Current trends in the management of bacterial vaginosis
- Authors: Apolikhina I.A.1,2, Afendieva Z.N.2
-
Affiliations:
- V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Issue: No 12 (2019)
- Pages: 193-196
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248770
- DOI: https://doi.org/10.18565/aig.2019.12.193-196
- ID: 248770
Cite item
Abstract
Despite the fact that ICD-10 does not encode bacterial vaginosis (BV) as a separate disease; today it is an unresolved reproductive health problem in women and along with other vulvovaginal infections remains one of the most common reasons for visiting a gynecologist. The paper reviews the data available in world and Russian literature on the efficacy and safety of dequalinium chloride used to treat BV. It discusses the mechanisms for the emergence of resistance of microorganisms to standard therapy regimens and the benefits of alternative treatments. The paper provides the 2018 clinical recommendations of the International Union Against Sexually Transmitted Infections (IUSTI)/World Health Organization (WHO) for the management of patients with pathological vaginal discharge. By taking into account a wide range of actions, evidence-based therapy effective against anaerobic and aerobic bacteria, fungi, and protozoa, the lack of resistance in microorganisms, and the possibility of use in all trimesters of pregnancy and during lactation, dequalinium chloride can be recommended as the drug of choice for the therapy of bacterial vaginosis caused by pathogens, including A. vaginae resistant to standard treatment regimens.
Full Text
About the authors
Inna A. Apolikhina
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: apolikhina@inbox.ru
Zulphiya N. Afendieva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: efendievaz@yandex.ru
References
- Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин /РОАГ/ под ред. В.Н. Прилепской, Е.Ф. Кира. 2019. 57 с.
- Borgdorff H., Armstrong S.D., Tytgat H.L., Xia D., Ndayisaba G.F., Wastling J.M., van de Wijgert J.H. Unique insights in the cervicovaginal Lactobacillus iners and L. crispatus proteomes and their associations with microbiota dysbiosis. PLoS One. 2016; 11(3): e0150767. https://dx.doi.org/10.1371/journal.pone.0150767
- Nasioudis D., Linhares I.M., Ledger W.J., Witkin S.S. Bacterial vaginosis: a critical analysis of current knowledge. BJOG. 2017. 124: 61-9. doi: 10.1111/1471-0528
- Mehta S.D. Systemic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis. 2012; 39(10): 822-30. doi: 10.1097/OLQ.0b013e3182631d89
- Verstraelen H., Verhelst R., Vaneechoutte M., Temmerman M. The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect Dis. 2010; 10: 81. doi: 10.1186/1471-2334-10-81.
- Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet.Gynecol.Surv. 2010; 65: 462-73. doi: 10.1097/OGX.0b013e3181e09621.
- Forsum U., Holst E., Larsson P.G., Vasquez A., Jakobsson T., Mattsby-Baltzer I. Bacterial vaginosis - a microbiological and immunological enigma. APMIS. 2005; 113: 81-90. doi: 10.1111/j.1365-2672.2011.04977.x
- Marrazzo J.M. A persistent(ly) enigmatic ecological mystery: bacterial vaginosis. J. Infect Dis 2006; 193: 1475-7. doi: 10.1086/503783
- Donders G.G., Van C.C., Bellen G., et al. Association between abnormal vaginal flora and cervical length as risk factors for preterm birth. Ultrasound Obstet. Gynecol. 2010. doi: 10.1002/uog.7568
- Kenyon C., Colebunders R., Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J. Obstet Gynecol. 2013; 209(6): 505-23. doi: 10.1016/j.ajog.2013.05.006
- Bretelle F., Rozenberg P., Pascal A., Favre R., Bohec C., Loundou A., Senat M.V., Aissi G., Lesavre N., Brunet J., et al. High Atopobium vaginae and Gardnerella vaginalis vaginal loads are associated with preterm birth. Clin Infect Dis. 2015; 60: 860-7. doi: 10.1093/cid/ciu966
- Российское общество дерматовенерологов и косметологов, Российское общество акушеров-гинекологов. Федеральные клинические рекомендации по ведению больных бактериальным вагинозом. Акушерство и гинекология. 2016; Приложение № 4: 42-8.
- Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis. 2009; 22(1): 82-doi: 10.1097/Qm.0b013e32832180c6
- Sherrard J., Wilson J., Donders G., Mendling W., Jensen J.S. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int. J. STD AIDS. 2018; 29(13): 1258-72. doi: 10.1177/0956462418785451
- Hugo W.B., Frier M. Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol. 1969; 17:118-27. PMCID: PMC377624
- Donders G.G., Zodzika J., Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother. 2014; 15: 645-57. doi: 10.1517/14656566.2014.881800
- Lopes dos Santos Santiago G., Grob P., Verstraelen H., Waser F., Vaneechoutte M. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes. 2012 ; 5: 151. doi: 10.1186/1756-0500-5-151